Currently out of the existing stock ratings of Christopher Raymond, 388 are a BUY (81.86%), 80 are a HOLD (16.88%), 6 are a SELL (1.27%).

Christopher Raymond

Work Performance Price Targets & Ratings Chart

Analyst Christopher Raymond, currently employed at RAYMOND JAMES, carries an average stock price target met ratio of 49.47% that have a potential upside of 40.19% achieved within 277 days. Previously, Christopher Raymond worked at PIPER SANDLER, BAIRD.

Christopher Raymond’s has documented 935 price targets and ratings displayed on 54 stocks. The coverage is on Healthcare, Consumer Cyclical, Energy, Basic Materials, Technology sectors.

Most recent stock forecast was given on COGT, Cogent Biosciences at 18-Feb-2026.

Wall Street Analyst Christopher Raymond

Analyst best performing recommendations are on ALXO (ALX ONCOLOGY HOLDINGS ).
The best stock recommendation documented was for ALXO (ALX ONCOLOGY HOLDINGS ) at 11/18/2020. The price target of $70 was fulfilled within 1 day with a profit of $5.5 (8.53%) receiving and performance score of 85.27.

Average potential price target upside

of $90.47 (21.14%) on REGN (REGENERON PHARMACEUTICALS).
of $78.35 (68.57%) on ALVR (ALLOVIR ).
of $54.4 (29.75%) on AMGN (AMGEN).

ABBV AbbVie ACRS Aclaris Therapeutics AIMT Aimmune Therapeutics AKBA Akebia Ther ALVR Allovir ALXN Alexion Pharmaceuticals AMAG AMAG Pharmaceuticals AMGN Amgen ARDX Ardelyx BIIB Biogen BMRN Biomarin Pharmaceutical COGT Cogent Biosciences DCPH Deciphera Pharmaceuticals LLC GRAY Graybug Vision INO Inovio Pharmaceuticals ONCR Oncorus RARE Ultragenyx REGN Regeneron Pharmaceuticals APTX Aptinyx BPMC Blueprint Medicines Corp CELG Celgene INZY Inozyme Pharma MGTX MeiraGTx Holdings PLC OTIC Otonomy RIGL Rigel Pharmaceuticals BOLD Audentes Therapeutics CBIO Catalyst Biosciences KNTE Kinnate Biopharma PRVL Prevail Therapeutics SLDB Solid Biosciences LLC XLRN Acceleron Pharma BCRX BioCryst Pharmaceuticals BHVN Biohaven Pharmaceutical Holding Co Ltd NUVL Nuvalent ALXO Alx Oncology Holdings KPTI Karyopharm Therapeutics RMTI Rockwell Medical SPHS Sophiris Bio VECT VectivBio Holding AG VRTX Vertex Pharmaceuticals QTTB Q32 Bio MNPR Monopar Therapeutics TYRA Tyra Biosciences ITOS Iteos Therapeutics TSHA Taysha Gene Therapies ABVX Abivax SA American Depositary Shares ALV Autoliv AM Antero Midstream Partners LP AP Ampco-Pittsburgh BP BP PLC ADR CE Celanese IT Gartner TS Tenaris SA ADR AGIO Agios Pharm

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Gary Nachman (RAYMOND JAMES)